Overview

• The double-blind, placebo-controlled trial enrolled 12 children with early-stage MIS-C who received larazotide or placebo four times daily for 21 days
• Participants treated with larazotide cleared SARS-CoV-2 spike antigen from the gut more rapidly and saw faster resolution of gastrointestinal symptoms than those on placebo
• No larazotide-related adverse events were reported during the treatment period or six months of follow-up, highlighting the drug’s safety profile
• Larazotide works by tightening intestinal junctions to prevent viral particles from leaking into the bloodstream
• Mass General Brigham investigators have launched a follow-on clinical trial to assess larazotide’s potential in alleviating long COVID symptoms